Efficacy, tolerability and safety of long-term darifenacin treatment in older patients with overactive bladder: Analysis of results from a 2-year, open-label extension study

被引：0
作者：
Dwyer, P.
Lheritier, K.
Steel, M.
机构：
[1] Mercy Hosp Women, Melbourne, Vic, Australia
[2] Novartis Pharma AG, Basel, Switzerland
来源：
NEUROUROLOGY AND URODYNAMICS | 2006年 / 25卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
125
引用
收藏
页码：657 / 658
页数：2
相关论文
共 3 条
[1]   Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder [J].
Haab, F ;
Stewart, L ;
Dwyer, P .
EUROPEAN UROLOGY, 2004, 45 (04) :420-429
[2]  
HAAB F, 2006, IN PRESS BJU INT
[3]   An investigation of dose titration with darifenacin, an M3-selective receptor antagonist [J].
Steers, W ;
Corcos, J ;
Foote, J ;
Kralidis, G .
BJU INTERNATIONAL, 2005, 95 (04) :580-586
1